VCEL - NASDAQ

Vericel Corporation

VCEL·NASDAQ

$34.74

+2.7%

HealthcareBiotechnology

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.77B

EPS0.3300

P/E Ratio110.29

Earnings Date07/30/2026

487.97M

Assets

13%

3Y+79.0%

5Y+137.0%

10Y+904.0%

133.33M

Total Liabilities

-5%

3Y+65.0%

5Y+87.0%

10Y+458.0%

354.64M

Total Equity

21%

3Y+84.0%

5Y+164.0%

10Y+1335.0%

Vericel Corporation Funding & Solvency Profile

VCEL · NASDAQ

Current Assets

Cash & Cash Equivalents100.09M

Net Receivables84.63M

Inventory17.56M

Other Current Assets7.74M

Total Current Assets247 M

Non-Current Assets

Property, Plant & Equipment173.17M

Goodwill & Intangible Assets5.62M

Long-Term Investments61.40M

Other Non-Current Assets341.00K

Total Non-Current Assets235 M

Total Assets

487.97M

Financial Health Analysis

Current Ratio

5.03x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.38x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

198 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

51% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Vericel Corporation Balance Sheet

VCEL • NASDAQ

Vericel Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Jun 2010	Jun 2008	Jun 2007	Jun 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	100.1M	74.5M	69.1M	51.1M	68.3M	33.6M	26.9M	18.3M	26.9M	23M	14.6M	30.3M	8.1M	13.6M	5.5M	31.2M	17M	16.5M	13.4M	9M
Short-Term Investments	37.4M	41.7M	40.5M	68.5M	35.1M	42.2M	42.8M	64.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6M	14.9M	34M
Cash & Short-Term Investments	137.5M	116.2M	109.6M	119.5M	103.4M	75.8M	69.7M	82.9M	26.9M	23M	14.6M	30.3M	8.1M	13.6M	5.5M	31.2M	17M	22.5M	28.3M	43M
Net Receivables	84.6M	61.4M	58.4M	46.5M	37.4M	34.5M	32.2M	23.5M	18.3M	17.1M	10.9M	8.2M	8K	28K	9K	25K	16K	58K	18K	78K
Accounts Receivables	84.6M	61.4M	58.4M	46.5M	37.4M	34.5M	32.2M	23.5M	18.3M	17.1M	10.9M	8.2M	8K	28K	9K	25K	16K	58K	18K	78K
Inventory	17.6M	17.4M	13.1M	16M	13.4M	9.4M	6.8M	3.6M	3.8M	3.5M	1.4M	1.9M	0.0	0.0	0.0	0.0	1K	1K	8K	1K
Prepaids	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	391K	-278K	0.0	0.0
Other Current Assets	7.7M	17.8M	24.6M	4.8M	4.2M	3.9M	3M	2.8M	1.6M	1.2M	464K	1M	409K	324K	636K	426K	383K	732K	1.6M	1.8M
Total Current Assets	247.4M	212.8M	205.6M	186.9M	158.5M	123.6M	111.7M	112.8M	50.5M	44.7M	27.3M	41.5M	8.5M	14M	6.2M	31.7M	17.8M	24.1M	30.2M	43.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	173.2M	173.3M	115.1M	57.4M	59M	57.7M	32.2M	5.9M	4.1M	3.9M	4M	2.9M	739K	1.2M	1.6M	1.1M	1.5M	2.2M	2.7M	1.2M
Intangible Assets	5.6M	6.3M	6.9M	7.5M	0.0	0.0	0.0	0.0	0.0	0.0	2.9M	3.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	5.6M	6.3M	6.9M	7.5M	0.0	0.0	0.0	0.0	0.0	0.0	2.9M	3.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	61.4M	39.9M	25.3M	20M	25.7M	24.1M	9.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	341K	556K	771K	1.3M	528K	211K	89K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Assets	240.5M	219.9M	148M	86.1M	85.2M	82M	41.6M	5.9M	4.1M	3.9M	7M	6.1M	739K	1.2M	1.6M	1.1M	1.5M	2.2M	2.7M	1.2M
Total Assets	488M	432.7M	353.7M	273M	243.7M	205.6M	153.2M	118.7M	54.6M	48.6M	34.3M	47.6M	9.2M	15.2M	7.7M	32.8M	19.3M	26.2M	32.8M	44.9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	15.8M	23.8M	22.3M	16.9M	9M	6.8M	6.3M	7.1M	5.6M	6.5M	7.6M	5.8M	2.4M	2.8M	2.2M	2.1M	1.7M	248K	344K	532K
Accounts Payable	15.8M	23.8M	22.3M	16.9M	9M	6.8M	6.3M	7.1M	5.6M	6.5M	7.6M	5.8M	2.4M	2.8M	2.2M	25K	0.0	0.0	344K	532K
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7M	248K	0.0	0.0
Accrued Expenses	0.0	3.5M	4M	6M	4.1M	2.1M	1M	6.7M	5.1M	4.1M	3.3M	3.3M	620K	383K	1M	796K	686K	355K	747K	1.2M
Short Term Debt	14.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	350K	779K	0.0	0.0	6K	34K	40K	214K	226K	479K	446K	439K
Capital Lease Obligations (Current)	0.0	9.3M	6.2M	4.3M	3M	4.4M	5.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6M	4.5M	0.0	0.0	941K	787K	1.8M	0.0	0.0	0.0	0.0	-439K
Other Current Liabilities	19.2M	13.7M	13.3M	10.3M	9.9M	9.2M	6.9M	964K	2.1M	1.4M	1.2M	2.7M	2.3M	2.4M	17.3M	26.8M	0.0	605K	563K	1.3M
Total Current Liabilities	49.1M	50.3M	45.7M	37.5M	26.1M	22.5M	19.8M	14.8M	13.1M	12.9M	12.1M	11.8M	5.3M	5.7M	20.7M	29.9M	1.7M	2.1M	3.5M	2.5M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.9M	9.4M	71K	109K	0.0	6K	40K	41K	79K	305K	783K	1.1M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.9M	9.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-27.9M	-11.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	876K	100K	0.0	0.0	0.0	0.0	1.7M	2.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	84.2M	90.5M	82M	43.3M	47.2M	48.9M	22.4M	1.7M	18.9M	11M	71K	109K	2.4M	6K	40K	41K	305K	783K	1.1M	356K
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.4M	0.0	0.0	0.0	0.0	0.0	0.0	-356K
Capital Lease Obligations	84.2M	98.9M	88M	47.6M	50.2M	53.3M	27.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	133.3M	140.8M	127.7M	80.7M	73.2M	71.3M	42.1M	16.5M	32M	23.9M	12.2M	11.9M	5.3M	5.7M	20.7M	29.9M	2M	2.9M	4.6M	2.5M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	38.4M	41.5M	38.4M	38.4M	41.6M	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	730.7M	684.8M	629.2M	593.2M	553.9M	510.1M	489.7M	471.2M	383M	329.7M	307.8M	305M	253.3M	243.2M	228.9M	231.3M	213.1M	203.2M	188M	184.5M
Additional Paid-In Capital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	471.2M	383M	329.7M	307.8M	305M	253.3M	243.2M	228.9M	225.1M	231.3M	213.1M	203.2M	188M
Retained Earnings	-376.3M	-392.8M	-403.2M	-400M	-383.3M	-375.8M	-378.7M	-369M	-360.9M	-343.6M	-324M	-307.7M	-287.8M	-275.3M	-241.8M	-222.2M	-195.8M	-179.9M	-159.7M	-142.2M
Accumulated Other Comprehensive Income/Loss	275K	4K	-100K	-978K	-154K	14K	21K	-39K	-6.6M	-7.1M	-5.6M	-71K	-4.1M	-3.6M	0.0	0.0	-3.1M	-2.6M	-1.9M	-2.5M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-471.1M	-382.6M	-329.5M	-307.8M	-305M	-253.3M	-243.2M	-228.9M	0.0	-507K	0.0	0.0	0.0
Total Stockholders' Equity	354.6M	292M	226M	192.3M	170.5M	134.3M	111.1M	102.2M	22.5M	24.7M	22.1M	35.6M	3.9M	9.5M	-13M	2.9M	17.3M	23.3M	28.3M	42.3M
Total Equity	354.6M	292M	226M	192.3M	170.5M	134.3M	111.1M	102.2M	22.5M	24.7M	22.1M	35.6M	3.9M	9.5M	-13M	2.9M	17.3M	23.3M	28.3M	42.3M
SUMMARY
Total Liabilities & Equity	488M	432.7M	353.7M	273M	243.7M	205.6M	153.2M	118.7M	54.6M	48.6M	34.3M	47.6M	9.2M	15.2M	7.7M	32.8M	19.3M	26.2M	32.8M	44.9M
Total Investments	98.8M	81.6M	65.8M	88.4M	60.8M	66.3M	52.1M	64.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6M	14.9M	34M
Total Debt	98.3M	98.9M	88M	47.6M	50.2M	53.3M	27.9M	0.0	17.2M	10.1M	71K	109K	6K	40K	80K	255K	784K	1.2M	1.5M	1.5M
Net Debt	-1.8M	24.3M	19M	-3.5M	-18.1M	19.7M	965K	-18.3M	-9.6M	-12.8M	-14.5M	-30.2M	-8.1M	-13.6M	-5.5M	-31M	-16.2M	-15.3M	-11.9M	-7.5M
Shares Outstanding	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535	50,571,535

SEC Filings

VCEL - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 18, 2026	May 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 01, 2026	April 29, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	March 19, 2026	April 29, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 13, 2026	January 13, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing

Showing 1 to 10 of 564 filings

Related Guides

Blog Categories

Continue your VCEL research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.